NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis → Biden FINISHED On June 13th? (From Paradigm Press) (Ad) Free BEAM Stock Alerts $23.81 -0.21 (-0.87%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$23.66▼$26.1550-Day Range$21.22▼$38.2852-Week Range$16.95▼$49.50Volume1.09 million shsAverage Volume1.42 million shsMarket Capitalization$1.96 billionP/E RatioN/ADividend YieldN/APrice Target$40.18 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Beam Therapeutics alerts: Email Address Beam Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside68.8% Upside$40.18 Price TargetShort InterestBearish17.03% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.42Based on 37 Articles This WeekInsider TradingSelling Shares$3.16 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.73) to ($4.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.48 out of 5 starsMedical Sector2205th out of 2,771 stocksBiological Products, Except Diagnostic Industry376th out of 462 stocks 3.2 Analyst's Opinion Consensus RatingBeam Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 5 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageBeam Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Beam Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.03% of the outstanding shares of Beam Therapeutics have been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 6.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth.Read more about Beam Therapeutics' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BEAM. Previous Next 1.9 News and Social Media Coverage News SentimentBeam Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 37 news articles for Beam Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 13 people have searched for BEAM on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,163,729.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beam Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Beam Therapeutics are expected to grow in the coming year, from ($4.73) to ($4.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -13.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -13.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Beam Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsMy system predicted the BA collapse – now it’s issuing an AI warningEven after several plane crashes and equipment malfunctions... a congressional hearing... and the worst PR firestorm in recent memory... The FTC's commission chair Lina Khan still deems Boeing (BA), "too big to fail" Click to see why a similar situation is currently brewing in the AI market... About Beam Therapeutics Stock (NASDAQ:BEAM)Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Read More BEAM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BEAM Stock News HeadlinesMay 14 at 4:00 PM | globenewswire.comBeam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressMay 14 at 5:54 AM | americanbankingnews.comBeam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Hold" from BrokeragesMay 13 at 8:59 AM | msn.comWirral patient first to access laser beam surgery to prevent epileptic seizuresMay 13 at 4:25 AM | americanbankingnews.comBrokers Issue Forecasts for Beam Therapeutics Inc.'s FY2024 Earnings (NASDAQ:BEAM)May 12 at 2:31 PM | msn.comLancashire NHS patients to access world-leading laser beam surgery to prevent epileptic seizuresMay 11 at 3:00 AM | americanbankingnews.comBeam Therapeutics Inc. (NASDAQ:BEAM) Forecasted to Earn Q2 2024 Earnings of ($1.10) Per ShareMay 11 at 1:28 AM | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)May 10, 2024 | americanbankingnews.comBarclays Lowers Beam Therapeutics (NASDAQ:BEAM) Price Target to $33.00May 10, 2024 | americanbankingnews.comBeam Therapeutics Inc. to Post Q3 2024 Earnings of ($1.23) Per Share, Leerink Partnrs Forecasts (NASDAQ:BEAM)May 10, 2024 | americanbankingnews.comWilliam Blair Weighs in on Beam Therapeutics Inc.'s Q2 2024 Earnings (NASDAQ:BEAM)May 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)May 9, 2024 | finance.yahoo.comBeam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 9, 2024 | investorplace.comBiotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing MedicineMay 8, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Travere Therapeutics (TVTX) and Oscar Health (OSCR)May 8, 2024 | globenewswire.comBeam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare ConferenceMay 8, 2024 | americanbankingnews.comBeam Therapeutics (NASDAQ:BEAM) Receives "Outperform" Rating from WedbushMay 7, 2024 | finance.yahoo.comBeam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed OverviewMay 7, 2024 | investorplace.comBEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | globenewswire.comBeam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial ResultsMay 6, 2024 | msn.comEpilepsy patients to be offered ‘game-changing’ laser therapy in NHS rolloutMay 2, 2024 | theglobeandmail.comThe best and worst recent ETF performers and the stock trends they revealMay 2, 2024 | finance.yahoo.comIBA signs contract with Yale New Haven Health and Hartford HealthCare to install Proteus®ONE proton therapy solution in Connecticut, USMay 1, 2024 | yahoo.comOU researchers develop new technology to improve bridges and roadsMay 1, 2024 | msn.comThe Days of Our Lives Superstar Casting That Would Blow Things *All* the Way Up - Not Just for Jada But Salem!May 1, 2024 | finance.yahoo.comBest Theratronics workers go on strike after company's 0% offerSee More Headlines Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/14/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BEAM CUSIPN/A CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees436Year Founded2017Price Target and Rating Average Stock Price Target$40.18 High Stock Price Target$57.00 Low Stock Price Target$20.00 Potential Upside/Downside+68.8%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,530,000.00 Net Margins-37.33% Pretax Margin-36.95% Return on Equity-15.46% Return on Assets-9.86% Debt Debt-to-Equity RatioN/A Current Ratio5.99 Quick Ratio5.99 Sales & Book Value Annual Sales$360.91 million Price / Sales5.43 Cash FlowN/A Price / Cash FlowN/A Book Value$12.04 per share Price / Book1.98Miscellaneous Outstanding Shares82,311,000Free Float78,854,000Market Cap$1.96 billion OptionableOptionable Beta1.88 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. John M. Evans M.B.A. (Age 46)CEO & Director Comp: $1.11MDr. Giuseppe Ciaramella Ph.D. (Age 55)President Comp: $933.2kMs. Terry-Ann Burrell M.B.A. (Age 47)CFO & Treasurer Comp: $711.15kDr. Feng Zhang Ph.D.Co-FounderDr. David R. Liu Ph.D.Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Nicole Gaudelli Ph.D.Co-FounderDr. Alexis Komor Ph.D.Co-FounderDr. Manmohan Singh Ph.D.Chief Technology OfficerDr. Gopi Shanker Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsFusion PharmaceuticalsNASDAQ:FUSNInhibrxNASDAQ:INBXGinkgo BioworksNYSE:DNARecursion PharmaceuticalsNASDAQ:RXRXADMA BiologicsNASDAQ:ADMAView All CompetitorsInsiders & InstitutionsAmerican International Group Inc.Bought 732 shares on 5/14/2024Ownership: 0.045%Vanguard Group Inc.Bought 413,892 shares on 5/10/2024Ownership: 9.208%Russell Investments Group Ltd.Bought 6,102 shares on 5/8/2024Ownership: 0.175%QRG Capital Management Inc.Bought 7,176 shares on 5/8/2024Ownership: 0.028%ProShare Advisors LLCBought 1,873 shares on 5/8/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions BEAM Stock Analysis - Frequently Asked Questions Should I buy or sell Beam Therapeutics stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares. View BEAM analyst ratings or view top-rated stocks. What is Beam Therapeutics' stock price target for 2024? 13 Wall Street research analysts have issued 12 month target prices for Beam Therapeutics' shares. Their BEAM share price targets range from $20.00 to $57.00. On average, they anticipate the company's share price to reach $40.18 in the next year. This suggests a possible upside of 68.8% from the stock's current price. View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts. How have BEAM shares performed in 2024? Beam Therapeutics' stock was trading at $27.22 at the beginning of the year. Since then, BEAM stock has decreased by 12.5% and is now trading at $23.81. View the best growth stocks for 2024 here. When is Beam Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our BEAM earnings forecast. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) posted its earnings results on Tuesday, May, 7th. The company reported ($1.21) earnings per share for the quarter, beating analysts' consensus estimates of ($1.42) by $0.21. The company earned $7.40 million during the quarter, compared to analyst estimates of $17.09 million. Beam Therapeutics had a negative net margin of 37.33% and a negative trailing twelve-month return on equity of 15.46%. The company's revenue for the quarter was down 69.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.33) earnings per share. Is Beam Therapeutics a good dividend stock? Beam Therapeutics (NASDAQ:BEAM) pays an annual dividend of $0.90 per share and currently has a dividend yield of 0.00%. Read our dividend analysis for BEAM. What ETFs hold Beam Therapeutics' stock? ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Innovation ETF (ARKK), Horizon Kinetics Medical ETF (MEDX) and WisdomTree BioRevolution Fund (WDNA). What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC). When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Beam Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.21%), Sumitomo Mitsui Trust Holdings Inc. (2.89%), Nikko Asset Management Americas Inc. (2.87%), Baillie Gifford & Co. (0.91%), Mirae Asset Global Investments Co. Ltd. (0.27%) and Russell Investments Group Ltd. (0.17%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Beam Therapeutics have any subsidiaries? The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..Read More This page (NASDAQ:BEAM) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressElon to Transform U.S. Economy? Porter & CompanyThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.